Skip to main content

Search

Reset all filters
569 Result(s)
Sort by

Respimat re-usable wins Pharmapack Eco-Design Award

Respimat re-usable wins Pharmapack Eco-Design Award

The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
“Rare diseases are quite common”

“Rare diseases are quite common”

Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
The little things

The little things

In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Living Independence

Living Independence

Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Metacam®

Metacam®

For the treatment of mastitis in lactating cows and for the control of pain associated with dehorning or surgery.